The 5 drugs tracked here made $50.1B of Eli Lilly’s 2025 revenue (77%) and lose US exclusivity by 2036. Since 2023, Eli Lilly has closed 8 acquisitions of $1B or more, worth $21.6B in total, plus 6 more where it disclosed only an "up to" price.
Bars are each drug's 2025 sales as a share of Eli Lilly’s total revenue ($65.2B). Only drugs tracked here are counted, so full exposure can be higher. Tap a bar for the drug's page.
| Closed | Company bought | Value | Area | What it brought | At closing |
|---|---|---|---|---|---|
| Aug 2023 | DICE TherapeuticsDICE 8-K, June 2023 | $2.4B | Immunology | Oral IL-17 inhibitors in development for psoriasis and other immune diseases | Pipeline only |
| Aug 2023 | Versanis BioLilly, July 2023 · Lilly, August 2023 | Up to $1.93BNot counted | Cardiometabolic | Bimagrumab, an antibody in development for obesity | Pipeline only |
| Dec 2023 | POINT BiopharmaPOINT, October 2023 · Lilly 10-K 2025 | $1.4B | Oncology | Radioligand cancer therapies, led by PNT2002 for prostate cancer | Pipeline only |
| Jul 2024 | MorphicLilly, July 2024 · Lilly 10-K 2025 | $3.2B | Immunology | MORF-057, an oral drug in Phase 2 for ulcerative colitis and Crohn's disease | Pipeline only |
| Mar 2025 | Scorpion TherapeuticsLilly, January 2025 | Up to $2.5BNot counted | Oncology | STX-478, a PI3Kα inhibitor in early trials for breast cancer | Pipeline only |
| Jul 2025 | SiteOne TherapeuticsLilly, May 2025 | Up to $1.0BNot counted | Neuroscience | STC-004, a non-opioid pain drug in development | Pipeline only |
| Jul 2025 | Verve TherapeuticsLilly, July 2025 | $1.0B | Cardiometabolic | One-time gene-editing treatments to lower cholesterolPlus a CVR worth up to $0.3B. | Pipeline only |
| Mar 2026 | Ventyx BiosciencesLilly, January 2026 · Lilly 10-Q, Q2 2026 | $1.2B | Immunology | Oral NLRP3 inhibitors for inflammatory diseases | Pipeline only |
| May 2026 | Orna TherapeuticsLilly, February 2026 | Up to $2.4BNot counted | Immunology | ORN-252, an in vivo CAR-T therapy for autoimmune diseases | Pipeline only |
| Jun 2026 | Ajax TherapeuticsLilly, April 2026 | Up to $2.3BNot counted | Oncology | AJ1-11095, an oral JAK2 inhibitor in early trials for myelofibrosis | Pipeline only |
| Jun 2026 | Centessa PharmaceuticalsLilly, March 2026 · Lilly, June 2026 | $6.3B | Neuroscience | ORX750 and other orexin agonists for narcolepsy and other sleep disordersPlus a CVR worth up to $1.5B. | Pipeline only |
| Jun 2026 | Kelonia TherapeuticsLilly, April 2026 · Lilly 10-Q, Q2 2026 | $3.25B | Oncology | KLN-1010, an in vivo CAR-T therapy for multiple myelomaUpfront payment; up to $3.75B more in milestones. | Pipeline only |
| Jul 2026 | Curevo, LimmaTech and Vaccine CompanyLilly, May 2026 · Lilly 10-Q, Q2 2026 | Up to $3.83BNot counted | Infectious disease | Vaccines in development, including amezosvatein for shinglesThree companies; Lilly gave one combined figure. | Pipeline only |
| Sep 2026 | AtaiBeckleyLilly, 2026 · Lilly, September 2026 | $2.8B | Neuroscience | Fast-acting psychedelic-derived treatments for treatment-resistant depressionPlus a CVR worth up to $1.0B. | Pipeline only |
| 8 counted · 6 not counted | $21.6B | ||||
Acquisitions of whole companies closed since January 2023 with a headline price of $1B or more. Values are the price Eli Lilly announced, excluding milestone payments unless noted. Where Eli Lilly disclosed only an "up to" price that includes milestones, the deal is listed but not counted in the total. Licensing deals are not included. Compare all 65 deals →
| Area | At risk by 2037 | Acquisitions since 2023 |
|---|---|---|
| Cardiometabolic | $40.8B | $1.0B |
| Oncology | $5.7B | $4.65B |
| Immunology | $3.6B | $6.8B |
| Neuroscience | – | $9.1B |
Eli Lilly has the most revenue at risk in cardiometabolic, but has spent the most on acquisitions in neuroscience. At risk is 2025 sales of tracked drugs losing US exclusivity by 2037; acquisitions are the headline value of counted deals closed since 2023.
The two figures measure different things. Revenue at risk is what the drugs earned in 2025. A deal's value is what Eli Lilly paid, not the sales it will bring in. None of the companies it bought had an approved product at closing, so any sales from them are years away and may never arrive. So this page shows the figures side by side rather than claiming how much of the gap the deals fill.
Lilly received notice that multiple companies had applied to sell generic tirzepatide before its patents expire, and said it intends to sue. Its US compound patent runs to 2036. Lilly 10-Q, Q2 2026
Revenue: Lilly 10-K. Drug sales and dates are sourced on each drug's page; each deal links to Eli Lilly’s announcement or filing in the table above.
See all 45 drugs on the patent cliff →